High cost of cancer treatment doesn’t reflect benefits, say specialistsBMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d6220 (Published 27 September 2011) Cite this as: BMJ 2011;343:d6220
- Nigel Hawkes
Care of patients with cancer has become “a culture of excess” in rich countries, says a team of specialists assembled by the Lancet. “We overdiagnose, overtreat, and overpromise. We are heading towards a crisis in medical-care delivery,” they say.
The report of the 37 strong commission, headed by Richard Sullivan from King’s Health Partners Integrated Cancer Centre in London, is uncompromising (Lancet Oncology 2011;12:933-80, doi:10.1016/S1470-2045(11)70141-3). It says that expensive new drugs often contribute modest benefits while imposing huge cost burdens.
Surgery, the mainstay of cancer care, is going the same way, with the increasing use of robot assisted surgery that drives costs up with no …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial